Market Overview - The Spain Car Rental Market is estimated to be valued at USD 5.95 billion in 2024 and is projected to grow to USD 7.47 billion by 2029, with a CAGR of 10.13% during the forecast period [1] - The market is driven by the increasing number of tourists and the growing car rental fleet size in Spain, supported by the country's rich cultural heritage and numerous attractions [1][4] Tourism Impact - Spain is a leading tourist destination, attracting millions of visitors annually, which significantly boosts the demand for car rentals, especially during peak seasons [3] - In 2022, tourist arrivals in Spain exceeded pre-pandemic levels, leading to a 30-40% increase in car rental bookings compared to 2021, with expectations for continued growth in 2023 and beyond [5] Consumer Preferences - There is a notable shift in consumer attitudes towards renting cars instead of owning them, particularly among tourists who prefer the flexibility of rental cars for their vacations [2] - The demand for economy cars is rising due to their affordability, with rental companies adjusting their offerings to include more budget-friendly options [6][7] Online Booking Trends - Online car rental booking is becoming more prevalent than offline booking, with new startups entering the market to provide pricing transparency and better customer service [8][9] - Technology advancements are expected to enhance the online booking experience, allowing for improved customer service and streamlined operations [9] Competitive Landscape - Major players in the Spanish car rental market include Europcar Mobility Group, Hertz Corporation, and Avis Budget Group, among others [2][10] - Uber has recently introduced a car rental service across 116 cities in Spain, expanding its offerings and providing a diverse fleet of vehicles from reputable rental companies [10]

Allogeneic, TSCM-rich dual CAR-T for the treatment of hematologic malignancies, including multiple myelomaNomination triggers $15 million milestone payment to Poseida, extending cash runway into early 2026Poseida Cell Therapy R&D Day to take place on Thursday, November 14 at 7 am PT / 10 am ETSAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with ...

Patient showed clinical activity after initial treatment, with necrosis, inflammation, and T cell infiltration observed in tumor biopsy from the lowest dose SAN JOSE, Calif., Oct. 15, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has administered the second dose of its CAR-T therapy to an individual patient. This follows a positive response after the initial treatment ...

Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studiesLead site Memorial Sloan Kettering Cancer Center (MSKCC); 4 disclosed clinical sites so farNXC-201 is the only one-time CAR-T treatment option being studied for relapsed/refractory AL Amyloidosis in U.S. clinical trials AL Amyloidosis, a disorder of plasma cells that leads to progressi ...

Amendment will allow a second dose of CAR-T therapy to suitable patientsSAN JOSE, Calif., Sept. 30, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it and partner Moffitt Cancer Center ("Moffitt") have submitted an amendment to the current protocol that governs its ongoing clinical trial utilizing a CAR-T therapy to treat ovarian cancer (NCT05316129).A key change in the pro ...

SAN JOSE, Calif., Sept. 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer Research Alliance's ("OCRA") International Gynecologic Cancer Conference taking place online September 25-27, 2024. The presentation, entitled "Autologous T Cells Engineered to Target Follicle Stimulating Hormone (FSH) Receptor in Recurrent Ovarian Cancer, A Pha ...

PHILADELPHIA, Sept. 17, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing the novel KIR-CAR platform technology, today announced that it has been awarded a $150,000 G-Rex Grant by ScaleReady™. This grant will support Verismo Therapeutics' ongoing efforts to optimize the development and manufacturing of its KIR-CAR platform using the G-Rex. The G-Rex Grant is part of ScaleReady's $20 million grant program aimed at advancing Cell and Gene Therapy (CGT) development and manufa ...

Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MASeptember 16, 2024 8:00 AM EDT | Source: Phio Pharmaceuticals Corp.Phio's INTASYL self-delivering RNAi technology enhances cell potency and yield in Adoptive Cell Therapy Marlborough, Massachusetts--(Newsfile Corp. - September 16, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune c ...

ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.The ProPakTM GMP Cytokine product consists of a weldable bag filled with liquid formulated GMP-grade cytokines, specifically interleukin-7 (IL-7) or interleukin-15 (IL-15), commonly used in the ex vivo manufacturing of CAR-T and TC ...

PARSIPPANY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) (the “Company”) announced today that its wholly-owned subsidiaries, Avis Budget Car Rental, LLC and Avis Budget Finance, Inc. (together, the “Issuers”), priced a private offering of $700 million aggregate principal amount of 8.250% senior notes due 2030 (the “Notes”), which represents a $200 million increase from the previously announced size of the offering. The Notes will have a maturity date of January 15, 2030. Th ...